Patents Examined by Jeffrey E. Russel
  • Cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof
    Patent number: 10787492
    Abstract: An improved cell-permeable (iCP)-SOCS3 recombinant protein and uses thereof. The iCP-SOCS3 recombinant protein may be used as protein-based anti-angiogenic agent by utilizing the platform technology for macromolecule intracellular transduction. The iCP-SOCS3 recombinant protein includes a SOCS3 protein and at least one advanced macromolecule transduction domain (aMTD)(s). The aMTD(s) is composed of 9-13 amino acid residues and has the following features (a)-(c): (a) having 3 or more amino acid residues independently selected from the group consisting of Ala, Val, Ile, Leu, and Pro; (b) having Proline as an amino acid residue corresponding to any one or more of positions 5, 7 and 8, and position 12 of its amino acid sequence; and (c) having an instability index of 40-60, an aliphatic index of 180-220, and a grand average of hydropathy (GRAVY) score of 2.1-2.6, according to Protparam computational formula.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: September 29, 2020
    Assignee: CELLIVERY THERAPEUTICS, INC.
    Inventor: Daewoong Jo
  • Methods and compositions for modulating transport of a drug
    Patent number: 10786542
    Abstract: Methods and pharmaceutical compositions for inhibiting or decreasing transport of a drug by a transporter of multidrug resistance-associated protein comprising a compound of Formula (V): wherein R1 and R2 are small peptides or modified peptides, are provided. The methods and compositions are useful in enhancing efficacy of drugs such as anti-inflammatory agents, neurological agents, thyroid agents, ocular agents, cancer chemotherapeutics, antibiotics, antimicrobials, antivirals and protease inhibitors to treat human immunodeficiency virus.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: September 29, 2020
    Inventors: Jeffrey D. Laskin, Ron Udasin, Lauren Aleksunes
  • P75antagonists and treatment of acute and chronic cardiac disease
    Patent number: 10786543
    Abstract: The present invention provides 75 kD transmembrane neurotrophin receptor (p75NTR) antagonists and their use in prevention and treatment of loss of function, and adverse remodeling, in cardiac tissues subject to acute or chronic hemodynamic stress. Uses of the antagonists with or without additional cardiotropic agents for improving contractility and for treatment of congestive heart failure are also provided.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 29, 2020
    Assignees: The Johns Hopkins University, Vanderbilt University
    Inventors: Nazareno Paolocci, Ning Feng, Carlo G. Tocchetti, Cyrus Takahashi, Bruce Carter
  • Anti-infective compound
    Patent number: 10774113
    Abstract: The invention relates to novel infective agents, the use thereof for the production of a pharmaceutical composition for the treatment and prophylaxes of a disease, preferably an infectious disease, a pharmaceutical composition comprising said compound, and to methods of producing said compounds. The invention further relates to a new probiotic configured for preventing or reducing the colonization by a pathogenic microorganism of an organ of a living being.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: September 15, 2020
    Assignee: Eberhard Karls Universitaet Tuebingen
    Inventors: Bernhard Krismer, Andreas Peschel, Stephanie Grond, Alexander Zipperer, Martin Christoph Konnerth, Daniela Janek, Hubert Kalbacher, Nadine Anna Schilling
  • Administration of serine protease inhibitors to the stomach
    Patent number: 10772861
    Abstract: The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 15, 2020
    Assignees: Leading Biosciences, LLC, The Regents of the University of California
    Inventors: Geert W. Schmid-Schonbein, Yung-Tsai (Andrew) Lee, Jeng Wei
  • Manufacture of Degarelix
    Patent number: 10765721
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: September 8, 2020
    Assignee: Ferring B.V
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • Compositions and methods related to inhibition of respiratory syncytial virus entry
    Patent number: 10765754
    Abstract: Disclosed herein are compositions and methods for inhibiting respiratory syncytial virus (RSV) entry into a host cell. Also provided herein are methods of identifying a peptide that interacts with the N-trimer of RSV F protein.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: September 8, 2020
    Assignees: Navigen, Inc., University of Utah Research Foundation
    Inventors: Brett D. Welch, Michael S. Kay, Debra Muir Eckert, Rena McKinnon, Michael Thomas Jacobsen
  • Chloride salt of TAT-NR2B9c
    Patent number: 10758589
    Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c, as chloride salts. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. The chloride salt of TAT-NR2B9c shows improved stability compared with the acetate salt form of prior formulations. Formulations of the chloride salt of TAT-NR2B9c are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: September 1, 2020
    Assignee: NoNO Inc.
    Inventor: Jonathan David Garman
  • Ultra-pure agonists of guanylate cyclase C, method of making and using same
    Patent number: 10745441
    Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: August 18, 2020
    Assignee: Bausch Health Ireland Limited
    Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
  • Compstatin analogs with improved pharmacokinetic properties
    Patent number: 10745442
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds comprise compstatin analogs in which the N-terminus contains an added or substituted component that improves (1) the peptide's binding affinity to C3 or its fragments, (2) the peptide's solubility in aqueous liquids, (3) the peptide's plasma stability, (4) the peptide's in vivo retention and/or (5) the peptide's bioavailability, as compared with an unmodified compstatin peptide under equivalent conditions. Pharmaceutical compositions and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: August 18, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Hongchang Qu, Daniel Ricklin
  • Method of synthesizing antagonist peptides for cell growth
    Patent number: 10745454
    Abstract: The embodiments herein disclose a method for synthesizing antagonistic peptide VEGF and bFGF. The method comprises synthesizing the antagonistic peptide for VEGF and bFGF and analyzing the purity of peptides. The quality of antagonistic peptide for VEGF and bFGF is analyzed by HPLC chromatogram and Mass spectrometry analysis. The biochemical activity of the antagonistic peptide for VEGF and bFGF is analyzed by competitive binding assay, cell proliferation assay, Matrigel assay for anti-angiogenic activity analysis, histopathological staining and Western blot analysis. The competitive binding assay of antagonistic peptide for VEGF and bFGF illustrate that peptides binds with cell receptors at a concentration of 2000 ng/ml. The cell proliferation assay illustrates that cell growth is arrested when antagonistic peptide for VEGF and bFGF are at a concentration of 2000 ng/ml.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 18, 2020
    Inventors: Seyed Mohsen Asghari, Somayeh Ehtesham
  • Influenza virus neutralizing peptidomimetic compounds
    Patent number: 10738083
    Abstract: The present invention relates to novel peptidomimetic compounds that are capable of binding to and/or neutralizing influenza viruses, in particular influenza A viruses of phylogenetic group 1, and to pharmaceutical compositions comprising such compounds. The invention also relates to the use of the peptidomimetic compounds in the diagnosis, prophylaxis and/or treatment of influenza virus infections.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 11, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Maria Van Dongen, Christophe Francis Robert Nestor Buyck, Wim Bert Griet Schepens, Jaroslaw Juraszek, Bart Rudolf Romanie Kesteleyn, Pierre Jean-Marie Bernard Raboisson, Boerries Brandenburg
  • Stabilized glycopeptide antibiotic formulations
    Patent number: 10729708
    Abstract: Disclosed herein are liquid formulations of glycopeptide antibiotics or pharmaceutically acceptable salts thereof, wherein glycopeptide antibiotic is selected from Vancomycin, Telavancin, Oritavancin, Teicoplanin and Dalbavancin. The formulations are suitable as infusion solutions or as a concentrate for making infusion solutions.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: August 4, 2020
    Assignee: Xellia Pharmaceuticals APS
    Inventors: Sabina Keser, Ivona Jasprica, Jerome LeCunff
  • ELP fusion proteins for controlled and sustained release
    Patent number: 10722590
    Abstract: The present disclosure provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The pharmaceutical formulations comprise a therapeutic agent including an active agent and an amino acid sequence capable of forming a reversible matrix at the body temperature of a subject. The disclosure provides improved pharmacokinetics for peptide and small molecule drugs.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: July 28, 2020
    Assignee: PHASEBIO PHARMACEUTICALS, INC.
    Inventors: James Jowett, David James Ballance
  • Chemical and biochemical adducts as biomarkers for organophosphate exposure
    Patent number: 10711037
    Abstract: Provided are methods for identifying OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts and compounds of Formula 1 for eliciting antibodies that specifically and selectively bind to the OP adducts, wherein the Formula 1 compounds have the structure of OP-Peptide-Linker-CP, wherein CP is a carrier protein, OP represents a structure corresponding to that of a reactive organic phosphorous compound covalently modifying a tyrosine residue hydroxyl group of the peptide of Formula I and the other variable groups are as described herein.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: July 14, 2020
    Assignee: Human Biomolecular Research Institute
    Inventor: John R. Cashman
  • Treatment of chronic ulcers
    Patent number: 10709760
    Abstract: The present invention provides a pharmaceutical formulation comprising LL-37 or a pharmaceutically-acceptable salt thereof and one or more pharmaceutically-acceptable diluent or carrier system, for use in a method of treatment of a chronic ulcer wound (such as a hard-to-heal venous leg ulcer or a diabetic foot ulcer), which method comprises: (a) topical application of the formulation to the ulcer; followed by (b) application of a dressing, and wherein the application of the formulation provides for a dose of LL-37 at the wound site that is below about 80 ?g of LL-37 applied per cm2 of wound area, and/or below about 26.7 ?g of LL-37 applied per cm2 of wound area, per day of treatment.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: July 14, 2020
    Assignee: Promore Pharma AB
    Inventors: Alvar Grönberg, Christine Dieterich, Margit Mahlapuu
  • Use of botulinum neurotoxin in the treatment of sialorrhea
    Patent number: 10709772
    Abstract: This invention relates to improved uses of botulinum neurotoxins in the treatment of sialorrhea or diseases or conditions relating to increased saliva production. In particular are botulinum neurotoxins disclosed which are administered into parotid and submandibular glands in a dose ratio between 1.45 to 1 and 1.7 to 1.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: July 14, 2020
    Assignee: Merz Pharma GmbH & Co. KGaA
    Inventors: Janos Csikos, Irena Pulte, Michael Althaus, Markus Krüer, Nico Wegener
  • Constructs having a SIRP-alpha domain or variant thereof
    Patent number: 10696730
    Abstract: The present disclosure features signal-regulatory protein ? (SIRP?) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-? constructs include a high affinity SIRP-? D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-?. The SIRP-? polypeptides or constructs include a SIRP-? D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein ? (SIRP-?) D1 variant and (ii) an antibody.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: June 30, 2020
    Assignee: ALX ONCOLOGY INC.
    Inventors: Jaume Pons, Bang Janet Sim, Steven Elliot Kauder, Hong Wan, Tracy Chia-Chien Kuo
  • Cell penetrating peptides for intracellular delivery of molecules
    Patent number: 10688194
    Abstract: A cell-penetrating peptide characterized in that it comprises an amino acid sequence X3X4X1X2X5X4X1X2X6X7X1X8X9X10X11X13 (SEQ ID No: 11), wherein X1 is F or W, X2 is F, W or Y, X3 is beta-A or S, X4 is K, R or L, X5 is E, R or S, X6 is R. T or S, X7 is E, R or S, X8 is none, F or W, X9 is P or R, X10 is R or L, X11 is K, W or R, X12 is R or F and X13 is R or K.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: June 23, 2020
    Assignee: Aadigen, LLC
    Inventors: Gilles Divita, Sebastien Deshayes, Karidia Konate, May Catherine Morris
  • Process for the preparation of cyclic depsipeptides
    Patent number: 10689419
    Abstract: Processes for preparing compounds of Formula (1) and Formula (2) are described, wherein X, Y, Z, R1-R7, L and n are defined herein. Intermediates useful in the preparation of the compounds of Formula (1) and Formula (2) are also described.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: June 23, 2020
    Assignee: ONKURE, INC.
    Inventors: Anthony D. Piscopio, Xiaoyong Fu, Feng Shi, Huayan Liu, Zhifeng Li